T1	Participants 106 134	patients with liver failure]
T2	Participants 290 317	subjects with liver failure
T3	Participants 486 728	74 MARS treatment sessions for 146 patients with liver failure and prothrombin time activity percentage (PTA) â‰¤ 40% were randomly divided into 2 groups: 92 MARS treatment sessions in the heparin-free group and 82 in the low-dose heparin group
